Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...
Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...
we are now also constructing our own investigator-initiated studies to help see if we can use precision immunotherapeutics to ...
The American Association for Cancer Research Annual Meeting 2025 will be held from April 25-30 in Chicago, Illinois, ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Pancreatic cancer patients may benefit ... initiated studies to help see if we can use precision immunotherapeutics to help provide good treatment options for these patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback